What is the Definition of Misclassification in Patients with Grade Group 2 prostate cancer Eligible for Active Surveillance and diagnosed with MRI targeted biopsy? A multi-institutional analysis with pathological confirmation
Should we routinely recommend a central review of magnetic resonance imaging of the prostate in men with positive mp-MRI? Implication for targeted biopsies
Pembrolizumab (Pembro) Plus Olaparib in Patients With Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer (mCRPC): Updated Results From KEYNOTE-365 Cohort A With a Minimum of 11 Months of Follow-Up for All Patients
Assessing The Need For Systematic Biopsies In Addition To Targeted Biopsies According To The Volume Of The Index Lesion Diagnosed At Mpmri. Results From A Large, Multi-Institutional Database
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study